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Abstract A 1670-bp cDNA coding for a novel human cysteine 
protease has been isolated from a monocyte-derived macrophage 
cDNA library. This cDNA predicts a 329-amino acid prepro- 
cathepsin with more than 50% identity to both human cathepsin 
S and cathepsin L and 94% identity to a rabbit cDNA, termed 
OC2, recently isolated from osteoclasts. Based on its high homol- 
ogy to OC2, we have named the human enzyme cathepsin O. 
Cathepsin O mRNA was identified as a single ~ 1.7 kb transcript 
in cultures of 15-day-old monocyte-derived macrophages, but was 
not expressed in human monocytes or alveolar macrophages. 
When transfected into COS-7 cells, cathepsin O displayed potent 
endoprotease activity against fibrinogen at acid pH. This novel 
endoprotease may play an important role in extracellular matrix 
degradation. 
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1. Introduction 
Cathepsins H, L, B, and S are papain family cysteine pro- 
teinases that have been implicated in a variety of physiological 
processes uch as proenzyme activation [1 3], enzyme inactiva- 
tion [4], antigen presentation [5-7], hormone maturation [8], 
tissue remodeling and bone matrix resorption [9-12]. Their 
proteolytic activities may also be relevant o human diseases 
such as neoplasia [13-16], arthritis [17], emphysema [18,19], and 
Alzheimer's disease [20,21]. Although they share identical ac- 
tive site amino acids (i.e. Cys, His, and Asn [22]) as well as a 
high degree of homology around their catalytic domains (85- 
95%), these classical cysteine proteases display distinct enzy- 
matic activities. For example, whereas cathepsins H and B are 
weak endopeptidases and primarily act as either an aminopep- 
tidase or carboxyl dipeptidase, respectively, only cathepsins S 
and L display strong endopeptidyl activities [23-25]. 
Within the papain family of cysteine proteinases sequence 
data are currently available for only the four enzymes discussed 
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above [26-30]. Prior biochemical work has suggested that addi- 
tional members of this family exist [31], but little information 
is available regarding their structure or function. Herein, we 
report the isolation of a novel human cysteine proteinase the 
expression of which is dramatically up-regulated during the in 
vitro maturation of peripheral blood monocytes into macro- 
phages. The human macrophage-derived cDNA bears strong 
homology to a putative cysteine protease recently isolated from 
rabbit osteoclasts [32], and the expressed protein product is 
shown for the first time to display potent endoproteolytic a tiv- 
ity. 
2. Materials and methods 
2.1. Cell culture and RNA preparation 
Human peripheral blood monocytes were adherence purified as de- 
scribed [33] and either harvested immediately or cultured for 15 days 
on 35-mm Petri dishes (Falcoln) in RPMI-1640 supplemented with 40% 
autologous serum. Total RNA was isolated from the adherent mon- 
ocytes and the 15-day-old monocyte-derived macrophages bythe gua- 
nidine isothiocyanate method as described [34]. Poly(A) ÷ RNA was 
purified by oligo(dT) cellulose column chromatography [35]. 
2.2. Construction and differential screening of the monocyte-derived 
cDNA library 
A cDNA library from 15-day-old monocyte-derived macrophages 
was prepared in 2ZAP Express vector (Stratagene) using the manufac- 
turer's protocol. Approximately 1 x 106 recombinant phage were differ- 
entially screened with 32p-labeled cDNA synthesized from either adher- 
ent monocytes or monocyte-derived macrophage poly(A) ÷ RNA [36]. 
Positive plaques that preferentially hybridized to monocyte-derived 
macrophage-specific cDNA probes were selected and subjected to a 
second round of differential hybridization. Approximately 800 macro- 
phage-specific clones remained positive after the second screening. Of 
the 300 clones sequenced thus far, a single clone displaying a novel 
sequence homology to the papain superfamily was identified for further 
analysis. 
2.3. Cloning and sequencing ofthe cathepsin 0 cDNA 
A partial ength cDNA clone of cathepsin O was labeled with [c~- 
32p]dATP using random hexamer extension (Multiprime, Amersham 
Corp.) and used as a probe to screen the macrophage cDNA library. 
Following primary, secondary and tertiary screening, individual posi- 
tive phages were isolated and resuspended in phage diluent. Insert sizes 
were determined by direct PCR amplification ofthe phage suspensions 
using T3 and M13 universal primers. The largest insert was automati- 
cally subcloned into pBK-CMV vector by co-infection with ExAssist 
helper phage according to the supplier (Stratagene). The entire insert 
was then sequenced by the dideoxy chain termination method (Se- 
quenase version 2.0; US Biochemical Corp.) as well as automatic se- 
quenator (Applied Biosystems) for both sense and antisense strands 
employing a primer walking strategy. The amino acid sequence was 
deduced from the cDNA sequence and further aligned with rabbit OC2 
and human cathepsin B, S, L or H with MacVector Version 4.1 software 
(Kodak, IBI). 
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2.4. Northern analysis 
Glyoxylated total RNA (10/lg) or poly(A) + RNA (1/lg) was electro- 
phoresed on a 1.2% agarose gel and the RNA transferred to Hybond 
N ÷ paper (Amersham Corp.). Blots were prehybridized in 50% forma- 
mide, 5 x SSPE, 5 x Denhardt's solution, and 0.1% SDS and salmon 
sperm DNA at 42°C [35]. Hybridization with the [c~-nP]dATP-labeled 
~800 bp cathepsin O cDNA fragment and 1.0 kb fragment of acidic 
ribosomal phosphoprotein [37] was carried out under identical condi- 
tions. Blots were then washed successively in 1 x SSPE and 0.1% SDS 
at 25°C for 5 min, and twice in 0.4 x SSPE and 0.1% SDS at 65°C for 
20 min each. 
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2.5. COS-7 cell transfection and endopeptidase assay 
The ~ 1.7 kb cDNA insert was released from pBK-CMV with EcoRI 
and XbaI (Boehringer-Mannheim) digestion and further subcloned into 
pcDNA-I expression vector (InVitrogen). This construct was trans- 
fected into COS-7 cell (American Type Culture Collection) with the 
DEAE-dextran/chloroquine method described previously [29]. Human 
cathepsin S was also subcloned into pcDNA-I and transfected into 
COS-7 cells. Two to three days post-transfection, cells were collected 
and lysed in buffer containing 1% of Triton X-100, 40 mM NaAc, and 
I mM EDTA, pH 4.5, for 1 h at 37°C with 10x 10 6 cells/ml. After 
centrifugation at 450 × g for 3 min, 12/11 of the supernatant was used 
ATT CGG CAC GAG CCG CAA TCC CGA TGG AAT AAA TCT AGC ACC CCT GAT GGT GTG CCC ACA CTT TGC 66 
TGC CGA AAC GAA GCC AGA CAA CAG ATT TCC ATC AGC AGG ATG TGG GGG CTC AAG GTT CTG CTG 
Met Trp Gly Leu Lys Val Leu Leu 
CCT GTG GTG AGC TTT GCT CTG TAC CCT GAG GAG ATA CTG GAC ACC CAC TGG GAG CTA TGG AAG 
Pro Val Val Ser Phe Ala Leu Tyr Pro Glu Glu Ile Leu Asp Thr His Trp Glu Leu Trp Lys 
ACC CAC AGG AAG CAA TAT AAC AAC AAG GTG GAT GAA ATC TCT CGG CGT TTA ATT TGG GAA AAA 
Thr His Arg  Lys Gln Tyr Asn Asn Lys Val Asp Glu Ile Ser Arg  Arg  Leu Ile Trp Glu Lys 
CTG AAG TAT ATT TCC ATC CAT AAC CTT GAG GCT TCT CTT GGT GTC CAT ACA TAT GAA CTG GCT 
Leu  Lys Tyr  Ile Ser Ile His Asn Leu Glu Ala Set Leu Gly Val His Thr Tyr  Glu Leu A la  
AAC CAC CTG GGG GAC ATG ACC AGT GAA GAG GTG GTT CAG AAG ATG ACT GGA CTC AAA GTA CCC 
Asn His Leu Gly Asp Met Thr Set Glu Glu Va] Val Gln Lys Met Thr Gly Leu Lys Val Pro 
TCT CAT TCC CGC AGT AAT GAC ACC CTT TAT ATC CCA GAA TGG GAA GGT AGA GCC CCA GAC TCT 
Ser His Ser Arg Ser Asn  Asp Thr  Leu Tyr Ile Pro Glu Trp Glu Gly Arg Ala  P ro  Asp Ser  
I 
^ 119 
GAC TAT CGA AAG AAA GGA TAT GTT ACT CCT GTC AAA AAT CAG GGT CAG TGT GGT TCC TGT TGG GCT 528 
Asp Tyr  Arg Lys Lys Gly Tyr Val Thr Pro Val Lys Asn Gln Gly Gln Cys Gly Ser Cvs Trp Ala 
141 
TTT AGC TCT GTG GGT GCC CTG GAG GGC CAA CTC AAG AAG AAA ACT GGC AAA CTC TTA AAT CTG AGT 594 
Phe Ser Ser Val  Gly Ala Leu Glu Gly Gln Leu Lys Lys Lys Thr Gly Lys Leu Leu A~ Leu Set 
163 
CCC CAG AAC CTA GTG GAT TGT GTG TCT GAG AAT GAT GGC TGT GGA GGG GGC TAC ATG ACC AAT GCC 660 
Pro G ln  Asn Leu Val Asp  Cys Val Ser Glu Asn Asp Gly Cys Gly Gly Gly Tyr  Met Thr Asn  Ala 
185 
TTC CAA TAT GTG CAG AAG AAC CGG GGT ATT GAC TCT GAA GAT GCC TAC CCA TAT GTG GGA CAG GAA 726 
Phe Gln Tyr  Val Gln Lys Asn Arg Gly Ile Asp Ser Glu Asp Ala Tyr Pro Tyr Val Gly G ln  Glu 
207 
GAG AGT TGT ATG TAC AAC CCA ACA GGC AAG GCA GCT AAA TGC AGA GGG TAC AGA GAG ATC CCC GAG 792 
Glu Ser Cys Met Tyr Ash Pro Thr  Gly Lys Ala Ala Lys Cys Arg Gly Tyr  Arg  Glu Ile Pro G]u 
I 
229 
GGG AAT GAG AAA GCC CTG AAG AGG GCA GTG GCC CGA GTG GGA CCT GTC TCT GTG GCC ATT GAT GCA 858 
Gly Asn Glu Lys A la  Leu Lys Arg Ala Val A la  Arg Val Gly Pro Val Ser Val Ala Ile Asp Ala 
251 
AGC CTG ACC TCC TTC CAG TTT TAC AGC AAA GGT GTG TAT TAT GAT GAA AGC TGC AAT AGC GAT AAT 924 
Ser  Leu Thr Ser Phe Gln Phe Tyr Ser Lys Gly Val Tyr Tyr Asp Glu Ser Cys Asn Ser Asp Asn 
273 
CTG AAC CAT GCG GTT TTG GCA GTG GGA TAT GGA ATC CAG AAG GGA AAC AAG CAC TGG ATA ATT AAA 990 
Leu Asn His Ala Val Leu Ala Val Gly Tyr Gly Ile Gln Lys Gly Asn Lys His Trp Ile Ile Lys 
295 
AAC AGC TGG GGA GAA AAC TGG GGA AAC AAA GGA TAT ATC CTC ATG GCT CGA AAT AAG AAC AAC GCC 1056 



















TGT GGC ATT GCC AAC CTG GCC AGC TTC CCC AAG ATG TGA CTCCAGCCAGCCAAATCCATCCTGCTCTTCCATTT 1130 









Fig. 1. cDNA sequence and deduced amino acid sequence of human cathepsin O. The numbers at the right side indicate the positions of nucleotides, 
and the amino acid positions are indicated by the numbers under the amino acids. Three potential glycosylation sites are double underlined. Single 
underlined amino acids depict the active site amino acids. The putative signal peptide is italicized. The hat (^) is the potential mature form of human 
cathepsin O start site (based on sequence similarities with other papain-type cathepsins [30]). 
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for endopeptidase analysis by adding 38 ,ul of assay buffer containing 
0.05% of Triton X-100, 20 mM NaAc, and 1 mM EDTA, pH 4.5, 1 pl 
of 100 mM cysteine, 50/lg/ml pepstatin A, and 125I-labeled fibrinogen 
at 1 mM final concentration. E-64 (10pM) was added where indicated 
to inhibit cysteine protease activity. Following a1 h incubation at 37 ° C, 
the reaction mixture was analyzed by SDS-PAGE on a 13% poly- 
acrylamide r solving el under educing conditions. The electrophore- 
sis was followed by Coomasie blue staining, destaining, el drying, and 
exposure to Kodak X-OMAT film at -80°C. 
3. Results 
3. I. Isolation of  a novel cysteine protease by differential 
hybridization of  a human macrophage cDNA library 
A cDNA library was prepared in 2ZAP by using total RNA 
isolated from 15-day-old human monocyte-derived macro- 
phages. Duplicate plaque lifts were hybridized by using 32p-la- 
beled first strand cDNA probes prepared from total RNA 
isolated from either 2-h adherent monocytes or the monocyte- 
derived macrophages. Of the ~ 300 cDNA clones preferentially 
expressed in the monocyte-derived macrophages that have been 
sequenced to date, a single ~ 800 bp fragment was identified that 
was predicted to encode a protein product with >50% identity 
to human cathepsin S and L as well as >95% identity to the 
recently sequenced rabbit OC2 isolated from rabbit osteoclasts. 
Furthermore, the fragment contained the triad of active site 
amino acids (i.e. Cys, His and Asn) characteristic of the cysteine 
protease family. This fragment was subsequently used to screen 





1 2 3 4  
Fig. 2. Northern blot analysis of human cathepsin O. (A) 10pg of total 
RNA from adherent monocytes or 15-day-old monocyte-derived mac- 
rophages were loaded onto lanes 1 and 2, respectively. The blot was 
hybridized with [0~-32p]dATP-labled human cathepsin O probe from 
nucleotide 520-1300 (Fig. 1). The slight distortion of the cathepsin O 
blot was due to the approximate co-migration ofthe transcript with the 
18 S ribosomal RNA and was not seen when poly(A) + RNA (1 pg) was 
used from adherent monocytes or macrophages (lanes 3 and 4, respec- 
tively). (B) The same Northern blot as in A hybridized with 1.0-kb 
acidic ribosomal phosphoprotein probe. 
3.2. cDNA library screening, DNA sequencing and amino acid 
sequence comparison 
Approximately 50 positive clones were isolated from 
-1 .5× 105 phages in the monocyte-derived macrophage li- 
brary. The largest insert detected was - 1.7 kb and was found to 
contain a 1661 bp cDNA encoding a 329 amino acid protein. 
As shown in Fig. 1, an examination of the protein sequence 
identified a putative (i) 15 amino acid signal sequence, (ii) cleav- 
age site at Arg I Jn-Ala ~5 between the pro- and mature forms of 
the enzyme and (iii) three possible N-glycosylation sites. A ~ 1.7 
kb cathepsin O transcript was detected in monocyte-derived 
macrophages (but not adherent monocytes; Fig. 2) indicating 
that the cDNA clone is likely to be full-length. Interestingly, 
this transcript could not be detected in human alveolar macro- 
phages even when the quantity of total RNA blotted was in- 
creased to 50 pg (not shown). 
Amino acid sequence alignment with other known human 
cysteine proteinases and rabbit OC2 shows that this novel pro- 
tein has 94% identity to rabbit OC2, 56% identity to human 
cathepsin S, 50% identity to human cathepsin L, 39% identity 
to cathepsin H, and only 20% identity to human cathepsin B
(Fig. 3). 
3.3. COS-7 cell transJection and endopeptidase assay 
To determine whether human cathepsin O can express en- 
dopeptidase activity, lysates prepared from control, mock- 
transfected, cathepsin O-transfected or cathepsin S-transfected 
COS-7 cells were incubated with tzsI-labeled fibrinogen at pH 
4.5 for 1 h at 37°C, and degradation assessed by SDS-PAGE/ 
fluorography. As shown in Fig. 4, the endogenous cathepsin B
activity found in untransfected or mock-transfected cell lysates 
[30] displayed only weak proteolytic activity that could be 
blocked by the general cysteine protease inhibitor, E-64 (lanes 
2 5). In contrast, when lysates recovered from cathepsin O- 
transfected cells were incubated with [~251]fibrinogen, all 3 
chains of the substrate (i.e. the ~z, fl, and Y chains), were com- 
pletely degraded (lane 8). As expected, cathepsin O-mediated 
proteolysis was also sensitive to inhibition by E-64 (lane 9). 
Interestingly, despite the fact that cathepsins O and S display 
the highest degree of homology among the human cysteine 
proteinases, the pattern of degradation products generated with 
cathepsin S-transfected lysates was distinct from that observed 
with cathepsin O (compare lanes 6 and 8). Furthermore, unlike 
cathepsin S, cathepsin O-dependent proteolytic activity could 
not be detected at pH 7.0 (not shown). Together, these results 
indicate that cathepsin O is a new member of the human cyste- 
ine proteinase gene family. 
4. Discussion 
The cDNA sequence reported in this communication codes 
for a 329-amino acid protein with 94% identity to the rabbit 
OC2 cDNA sequence recently cloned from osteoclasts [32]. 
Because this novel protein most likely represents the human 
counterpart of rabbit OC2, we named it cathepsin O to reflect 
the relationship between the two gene products. Like cathepsin 
O, the reported cDNA sequence for OC2 was predicted to 
encode a cysteine protease. However, the rabbit enzyme was 
not expressed or isolated and no prior demonstration of en- 
zymic activity had been reported. In this study, we have demon- 
strated that cathepsin O is a potent endoprotease at acidic pH. 
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Human Cat  0 : 
Rabb i t  Cat  O:  
Hu lnan  Cat  S : 
Human Cat  L :  * N P T L - I * A A F C L G I * S A T 
Human Cat  H :  * * A T L - P * * C A G A W L L G V P 
Human Cat  B :  * * Q * w A S * C C L L * L A N A R S 
HCO:  Y N N  KV D - - E I S R R L I W E K N L K Y  I S 
RCO:  * * S * * * - - * * * * * * * * * * * * * }{ * * 
HCS:  * * * * * * - - * * * * * * * * * * * * * * * *  
HCL:  NR LY  G M N  E * GW * * AV * * * * M*  M * E 
HCH:  W M  S * H R K T Y S T E E Y H H R L Q T F A S N 
HCB:  T T W Q A G H N F Y N V D M S  Y L *  R*  C G T F  
HCO:  L G DM T S E E VV Q K M T  G L K V P L S H S R 
RCO:  * * * * * * * * * * * * * * * * * * * P * R * H 
HCS:  * * * * * * * * * * * * * * * * * * * - * * * *  
HCL:  F * * * * * * * F R*  V ' N *  F Q N R  K P R K G  
HCH:  F S * * S F A*  I KH * Y L W S E 
HCB:  S F*  AR - * QW P*  C P * I - * 
HCO:  Y R K KG - Y V T P V K N Q G Q  C G S C W A F S  
RCO : * * * * * - * * * * * * * * * * * * * * * * * * 
* * * * * * * * * _ * * * * * * * * * * * * * * * * * *  
* * * * * * * * * _ * * * * * * * * * * * * * * * * * *  
= 
HC**  * * * * * N F * S  * * * * * * * *  * * * * * *  * 
• CB . . . . . . . . . . . . . .  * * S * * * ~ * * * G 
HCO P Q N L V D C V S E . . . . .  ND G C G G G Y M  
RCO * * * * * * * * * * . . . . .  * Y * * * * * * * 
HCS * * * * * * * * * * * * * - - * * * * * * * * *  
HCL  * * * * * * * - * * * * * - - * * * * * * * * *  
H C H : E * Q * * * * A Q D F N - - - * Y * * Q * * L P  
HCB:  V S A E * L L T C C G  S M C G * *  * N * *  * P 
HCO:  Y - V G  Q E E S  C M Y N P T G K A A K C R G Y -  
RCO : * - * * * D * * * * * * * * * * * * * * * * * - 
HCS:  * -  K A M D Q K * Q * D S K Y R *  * T * S K * -  
HCL:  * - E AT  * * * * K*  * * *Y  S V*  N D T *  F 
HCH:  * - Q *  K D G Y * K F Q * - *  **  I G F V K D V  
HCB:  S H*  * C R PY  S I P P C E H H V N G  S R P PC  
HCO:  V S V A  I D A S  L T S  F Q F Y S K G V Y Y D E S  
RCO:  * * * * * * * * * * * * * * * * * * * * * * * N 
HCS:  * * * * * * * * * * * * * * * * * * * * * * * *  
HCL:  I * * * *  * * G H E * * L * * K E *  I * F E P D  
HCH:  * * F * F E V T Q D - * M M * R T *  I * S S T *  
HCB:  T Y K Q D K H Y G Y N S  Y S V * N S E  K - *  IM  
HCO : . . . . . . . . . . . . . . . . .  H 
m 
RCO : . . . . . . . . . . . . . . . . .  * 
HCS : . . . . . . . . . . . . . . .  *~ E 
HCL : . . . . . . . . . . . . . . .  
HCH : . . . . . . . . . . . . . . . . .  * 
HCB:  L Y K S G V Y Q It V T G EMN G G~ 
HCO:  W G E N W G N K G Y I L M A R N K N 
RCO : * * * S * * * * * * * * * * * * * * 
HCS:  * * H * F * E E * * * R * * * * * G 
HCL:  * * * E * * M G * * V K * * K D R R 
HCH:  * * P Q * * M N * * F * I E * G * * 
HCB:  * N T D * * D N * F F K I L * G Q D 
M W G L K - V L L L P V V S F A - L Y P E E I L D T H  
* * * * * _ * * * * * * * * * * _ * * * * * * * * * *  
* K R * V C * * * V C S S A V * Q * H K D P T * * H *  
L T F - - * H S  
V C G A A E L S  
R P S F H P V S  
I H N L E A S L  
* * * * * * * *  
L * * * * H * M  
L * * Q * Y R E  
W R K I N * H N  
L G G P K P P Q  
W E - L W K K T H R K Q  
* * - * * * * * Y S * *  
* H - * * * * * Y G * *  
L * A Q * T * W K A M H  
V N S * E * F - * F * S  
D * - * V N Y V N K R N  
- G V H T Y E L A M N H  
_ * * * * * * * * * * *  
- * M * S * D * G * * *  
- * K * S F T M * * * A  
N * N * * F K M * L * Q  
R V M F * E D * K L P A  
- S N D T L Y I P E W E G R A P D S V D  
- * * * * * * * * D * * * * T * * * I *  
- R * I * - * K S N P N R I L * * * * *  
- K V F Q E P L F Y - * - - * * R * * *  
P Q N C S A T K * * Y L R G T G P Y  . . . .  * P * * *  
E I  . . . .  * - - - *  . . . . . . . . . . . . . . . .  
S V G A L E G Q  
* * * * * * * *  
A * * t * * A *  
A T * * * * * *  
T T * * * * S A  
A * E * I S D R  
T N A F Q Y V Q  
* * * * * * * *  
* T * * * * I I  
D Y * * * * * *  
S Q * * E * I L  
A E * W N F W T  
R E I P E G N E  
* * * * * * * *  
T * L * Y * R *  
V D * * K Q - *  
A N * T I Y D *  
T G E G D T P -  
L K K K T G K L L N L S  
* * * * * * * * * * * *  
* * L * * * * * V T * *  
M F R * * * R * I S * *  
I A I A * * * M * S * A  
I C I H * N A H V S V E  
K N R G I D S E D A Y P  
R * * * * * * * * * * *  
D * K * * * * D A S * *  
D * G * L * * * E S * *  
Y * K * * M G * * T * *  
R - K * L V * G G L * E  
K A L K R A V A R V G P  
* * * * * * * * * * * *  
D V * * E * * * N K * *  
* * * M K * * * T * * *  
E * M V E * * * L Y N *  
* C S * I C E P G Y S *  
C N - - S D N L N  . . . . . . . . . . .  
*S  - * * * V *  - - -  
* - - - T Q * V *  . . . . . . . . . . .  
* S - - * E D M D  . . . . . . . . . . .  
* H K T P * K V *  . . . . . . . . .  
A E I Y K N G P V E G A F S V Y S D F L  
A V L A V G Y G I  . . . .  Q K - G N K H W I I K ~ S  
* * * * * * * * *  . . . .  * * _ * * * * * * * * * *  
G * * V * * * * D  . . . .  L N - * K E Y * L V * * *  
G * * V * * * * F E S T E S D - N * * Y * L V * * *  
* * * * * * * r E  . . . . .  * N * I P Y * * V * * *  
* I R I L * W * V E N  . . . . .  * T P Y * L V A * *  
N A C G I A N L A S F P K M S T O P !  
* * * * * * * * * * * * * * S T O P !  
* H * * * * S F P * Y * E I S T O P !  
* H * * * * S A * * Y * T V S T O P !  
- M * * * * A C * * Y * I P L V S T O P !  
- H * * * E S E V V A G I P R T D Q Y W E K I S T O P I  
Fig. 3. Amino acid alignment of human cathepsin O with other classical cathepsins and rabbit OC2. Asterisks indicate identical amino acids as in 
human cathepsin O. The papain cysteine protease active site amino acids are double underlined. 
As shown in Figs. 1 and 3, human cathepsin O has much higher 
homology to cathepsins S and L than either cathepsin H or 
cathepsin B. This suggests that the enzymatic activities of 
cathepsin O may be more like either cathepsin S or L and less 
like cathepsins H and B, as is also suggested by its potent 
endoprotease activity. As an aside, it should be noted that it is 
possible that the enzyme we have termed cathepsin O bears 
structural resemblance or identity to a previously reported col- 
lagenalytic enzyme, cathepsin N [31]. Rabbit cathepsin N, iso- 
lated from spleen, was reported to be ~ 34 kDa in size. Although 
the predicted size of cathepsin O based on its amino acid se- 
quence is only 24 kDa, we have detected a ~38 kDa band by 
active site labeling of transfected lysates (unpublished observa- 
tion). Whether the radiolabeled species is the mature form of 
cathepsin O is currently unclear. In addition, there is currently 
no sequence information available for cathepsin N. Thus, the 
relationship, if any, between cathepsin O and the enzyme previ- 
ously termed cathepsin N remains to be defined. 
Although the cathepsin O sequence is similar to that of 
cathepsins L and S, its pattern of cellular expression is distinct. 
While human monocytes ignificantly increased mRNA levels 
for cathepsins B, L and S within a few days of in vitro culture 
(V.Y.R., S.M.B. and S.J.W., unpublished observation), cathep- 
sin O mRNA levels did not increase until late in the maturation 
process. Similarly, human alveolar macrophages express 
cathepsins B, L, and S [25,29], but cathepsin O mRNA could 
not be detected. Interestingly, the appearance of the cathepsin 
O transcript in monocyte-derived macrophages correlates with 
the appearance of a highly degradative phenotype in these cells 
(V.Y.R., S.M.B. and S.J.W., unpublished observation). The 
relationship between the expression of cathepsin O by cultured 
macrophages and their degradative potential, however, is cur- 
rently unclear. Nonetheless, the demonstration that cathepsin 
O can express endoprotease activity suggests that the enzyme 
may participate in macrophage-mediated matrix remodeling 
and, by analogy to the pattern of expression reported for OC2, 
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Fig. 4. Endopeptidase assay of human cathepsin O with ~25I-labeled human fibrinogen. Cell lysates (12/21) of cathepsin-expressing transfectants 
indicated in the figure were mixed with ~25I-fibrinogen for 1 h at pH 4.5 and the reaction mixtures electrophoresed and developed by autoradiography 
as described in the text. Lane 1 is undigested fibrinogen. The 0t, fl, and 7' chains of fibrinogen are indicated. Lanes 2-9 are fibrinogen digestions with 
lysates from untransfected COS cells (2,3); or COS cells transfected with pcDNA-I, mock (4,5); pcDNA-I/cathepsin S (6,7) and pcDNA-I/cathepsin 
O (8,9), respectively. Pepstatin was added to all lysates and E-64 was added to lysates used in lanes 3, 5, 7 and 9. 
in osteoclast-mediated bone resorption as well. Further studies 
are required to define those conditions wherein cathepsin O is 
expressed and the role that the proteinase plays in the progres- 
sion of matrix-destructive conditions. 
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